|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigations |
Children's Hospital of Pittsburgh, Pittsburgh, PA (R.I.J., L.F., I.F.P.); Ohio State University, Columbus, OH (A.Y.); Baylor College of Medicine, Houston, TX (S.M.B.); University of Southern California, Los Angeles, CA (T.Z.); Children's Oncology Group, Arcadia, CA (T.Z., A.M.I.); The University of Texas Southwestern Medical Center, Dallas, TX (R.T.); University of California, San Francisco, San Francisco, CA (M.D.P.); Children's Hospital of Philadelphia, Philadelphia, PA (P.C.A.); USA
Address correspondence to Regina Jakacki, Children's Hospital of Pittsburgh, 3705 Fifth Ave., 4B Suite 385, Pittsburgh, PA 15213, USA (regina.jakacki{at}chp.edu).
A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas. Response was assessed following two courses of therapy at the MTD. Temozolomide was administered to cohorts of patients at doses of 100, 125, 160, or 200 mg/m2 on days 1-5, along with 90 mg/m2 lomustine on day 1. Two courses of lomustine/temozolomide were given prior to radiation therapy (RT) and up to six courses were administered afterward. Thirty-two patients were enrolled. Dose-limiting myelosuppression was seen in two of three patients enrolled at the 200 mg/m2 dose level. One of 14 patients in the expanded MTD cohort (160 mg/m2) experienced dose-limiting thrombocytopenia. After two courses at the MTD, one patient with a 5-mm enhancing nodule postoperatively had a complete response, one patient with a large residual temporal lobe glioblastoma had a partial response, and eight patients had stable disease. Several patients developed transient radiographic worsening after completing RT. Median 1- and 2-year overall survivals at the MTD were 60% ± 13% and 40% ± 13% with a median of 17.6 months. Thirteen of 20 patients (65%) who underwent MRI scans within 6 months prior to death developed metastatic disease. In conclusion, when administered with 90 mg/m2 lomustine on day 1, the MTD of temozolomide is 160 mg/m2/day x 5. Radiographic changes following RT make determination of early tumor progression difficult. Metastatic disease is common prior to death.
Key Words: CCNU (lomustine) • malignant glioma • pediatrics • temozolomide
|
|
